Organ function support in patients with coronavirus disease 2019: Tongji experience.
10.1007/s11684-020-0774-9
- Author:
Yong LI
1
;
Fan HE
2
;
Ning ZHOU
3
;
Jia WEI
4
;
Zeyang DING
5
;
Luyun WANG
3
;
Peng CHEN
3
;
Shuiming GUO
2
;
Binhao ZHANG
5
;
Xiaoning WAN
3
;
Wei ZHU
6
Author Information
1. Department of Respiratory and Critical Care Medicine, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
2. Department of Nephrology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
3. Department of Cardiology, Department of Internal Medicine and Genetic Diagnosis Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
4. Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
5. Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
6. Department of Emergency and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. tjjzkzw512@163.com.
- Collective Name:Multidisciplinary Team for COVID-19
- Publication Type:Journal Article
- Keywords:
COVID-19;
organ function support;
severe and critical type
- MeSH:
Antiviral Agents;
therapeutic use;
Betacoronavirus;
Coronavirus Infections;
drug therapy;
therapy;
Humans;
Oxygen Inhalation Therapy;
Pandemics;
Pneumonia, Viral;
therapy;
Respiration
- From:
Frontiers of Medicine
2020;14(2):232-248
- CountryChina
- Language:English
-
Abstract:
Coronavirus disease 2019 (COVID-19) is a highly contagious disease and a serious threat to human health. COVID-19 can cause multiple organ dysfunction, such as respiratory and circulatory failure, liver and kidney injury, disseminated intravascular coagulation, and thromboembolism, and even death. The World Health Organization reports that the mortality rate of severe-type COVID-19 is over 50%. Currently, the number of severe cases worldwide has increased rapidly, but the experience in the treatment of infected patients is still limited. Given the lack of specific antiviral drugs, multi-organ function support treatment is important for patients with COVID-19. To improve the cure rate and reduce the mortality of patients with severe- and critical-type COVID-19, this paper summarizes the experience of organ function support in patients with severe- and critical-type COVID-19 in Optical Valley Branch of Tongji Hospital, Wuhan, China. This paper systematically summarizes the procedures of functional support therapies for multiple organs and systems, including respiratory, circulatory, renal, hepatic, and hematological systems, among patients with severe- and critical-type COVID-19. This paper provides a clinical reference and a new strategy for the optimal treatment of COVID-19 worldwide.
